Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.
about
NPM1 deletion is associated with gross chromosomal rearrangements in leukemiaRibosomopathies: human disorders of ribosome dysfunction.The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS.Errant innate immune signaling in del(5q) MDS.Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.Ribosome defects in disorders of erythropoiesis.Nucleolar stress with and without p53.A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.When ribosomes go bad: diseases of ribosome biogenesis.The emerging importance of ribosomal dysfunction in the pathogenesis of hematologic disorders.Hdac3 is essential for the maintenance of chromatin structure and genome stability.Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-κB gene networkGenetic deletions in AML and MDS.Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.Diamond Blackfan anemia treatment: past, present, and future.Clinical utility of lenalidomide in the treatment of myelodysplastic syndromesDexamethasone and lenalidomide have distinct functional effects on erythropoiesis.Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q).Myelodysplasia-associated mutations in serine/arginine-rich splicing factor SRSF2 lead to alternative splicing of CDC25CAlterations in the ribosomal machinery in cancer and hematologic disorders.Radiation Induced Apoptosis of Murine Bone Marrow Cells Is Independent of Early Growth Response 1 (EGR1).Important genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway.Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.Haplo-insufficiency: a driving force in cancer.Biology and treatment of the 5q- syndrome.Molecular dissection of the 5q deletion in myelodysplastic syndrome.Haploinsufficiency of Tumor Suppressor Genes is Driven by the Cumulative Effect of microRNAs, microRNA Binding Site Polymorphisms and microRNA Polymorphisms: An In silico Approach.Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletionA long lasting puzzle for -7/7q- syndrome.Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring.Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.Modeling Myeloid Malignancies Using Zebrafish.The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.Isolated del(5q) in Patients Following Therapies for Various Malignancies May Not All Be Clinically Significant.The 5q- syndrome: biology and treatment.Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q
P2860
Q28749228-A73FC851-0EB8-4B62-B5E6-D02FC47DDEF9Q33806050-BB4E905F-BAE3-406F-ABBE-FB7B594A63F9Q33839824-BA7E63CE-FB8F-4E42-8F96-3F43D6AEDBB3Q33987039-753D280D-3348-4DEF-B291-A4FEDF0F6EAAQ33987086-8E342F71-6632-4B04-BAD0-0E2F6583532DQ34161561-666F1D99-F8CC-408A-925D-5906BDCD58EFQ34183329-64EEC8EB-09C4-4A76-993C-31A9FABA0E7EQ34220013-CA85D85A-5F75-47AE-8CFE-5F8AEFD7C832Q34248659-F19FD937-5762-47DF-B2A0-376644E0BA77Q34358020-ACDC8AE4-423A-4271-83CB-25A74AD4D21DQ34417264-BB5E1C63-ACDC-44AD-8815-C5F9A18AE2CEQ34540749-0545C4D2-A4A7-4991-86D5-E3C764881334Q34545116-EF4625D7-2588-4D9A-82CF-D048271B92DDQ34707415-BDE21437-188A-464F-B7FA-CDC14CEAFFCEQ34778028-29BC437C-DC58-42C7-B7E0-981F80FE50C4Q34783754-87FCEF2C-B2D2-4C48-959A-49F1CA439996Q35182727-3E33828C-05C6-4B94-930B-745EEE344D66Q35525418-0451352E-E31E-489B-ACA5-D5DA7C2E266EQ36064278-7F8547F0-4710-44AE-B45C-03103A63961FQ36110604-05AFFB97-8F76-4892-B250-8860F14D5350Q36222432-B0D763B0-7DF7-4EC3-A163-552E7DDE9D35Q36247578-6B752131-8088-4E8A-8D5A-9B74656535E2Q36417421-B28FD089-954F-467D-A83E-C13B05C0E19EQ36909178-18D8BAD6-09DE-4029-AB67-BE883D3024CDQ37799831-9A10B10E-AD85-486F-AACA-729782EF38C1Q37815124-0AEE7310-C062-43E8-99EF-325B970F2A30Q37842349-251698CE-7EF9-4630-AF76-287763182D92Q37937810-38ED3C38-CF08-4D4D-AE6A-7C7A1424A4E4Q41932257-8C2EB123-01D3-4522-B56F-091A72C4432BQ42253318-F4CACC6E-57CA-4FF9-A1B1-AFE67FF1A244Q42405743-CE3B8A4A-09ED-4F79-94B1-EB7F705B3AC2Q42586752-0B8FFF06-70F7-4DC1-95BD-A829D41312F1Q42879201-00182CD0-24B4-41F4-B0C3-83EE73D358ECQ44850006-0DB1FCD7-532E-4D42-A8A9-AD8B1D1E4A0DQ47108992-6DBA66D8-3DA2-4D16-8420-2CEC236A4099Q47301676-76A747AA-D0BE-4E33-ADBE-17862D0938A6Q52777531-53642734-FF48-46CD-9BA3-BB394760228FQ53469467-446E486F-8095-411A-B36E-B6F360770C86Q54539679-2B92E789-BAC2-4ECE-853E-0A6A6FFB14D0Q58010138-2BA86CE3-EC7F-4AD9-8357-82F4F2357A18
P2860
Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Deletion 5q in myelodysplastic ...... emizygous deletions in cancer.
@en
Deletion 5q in myelodysplastic ...... emizygous deletions in cancer.
@nl
type
label
Deletion 5q in myelodysplastic ...... emizygous deletions in cancer.
@en
Deletion 5q in myelodysplastic ...... emizygous deletions in cancer.
@nl
prefLabel
Deletion 5q in myelodysplastic ...... emizygous deletions in cancer.
@en
Deletion 5q in myelodysplastic ...... emizygous deletions in cancer.
@nl
P2860
P356
P1433
P1476
Deletion 5q in myelodysplastic ...... emizygous deletions in cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2009.53
P577
2009-03-26T00:00:00Z